Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
1.450
+0.060 (+4.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coherus Bio
< Previous
1
2
3
Next >
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
August 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 27, 2024
– Transaction aligns with Coherus’ strategic focus on oncology –
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
June 05, 2024
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
May 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 09, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
April 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
March 04, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
February 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
February 21, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
January 22, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 18, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of LOQTORZI™
January 02, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
December 26, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
December 11, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces CFO Transition Plans
December 07, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
December 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical
November 28, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
November 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
November 03, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.